Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Signaling Pathway Mutations Cooperate with the PICALM/MLLT10 Fusion in a Knock-in AML Mouse Model

Rhea H. Desai, Peter J. Browett, Purvi M. Kakadia, Stefan K. Bohlander

Blood (2023) 142 (Supplement 1): 4128.

https://doi.org/10.1182/blood-2023-178915

Published: 2023

Journal Articles

Picalm/MLLT10 Expression in Zebrafish Is Associated with an Increase of Hematopoietic Stem Cells and Leads to Leukemia

Omid Delfi, Peter J. Browett, Maryam Saberi, Yih Jian Sung, Purvi M. Kakadia, Stefan K. Bohlander

Blood (2023) 142 (Supplement 1): 5698.

https://doi.org/10.1182/blood-2023-179490

Published: 2023

Journal Articles

Drug Repurposing in a Zebrafish AML Model

Maryam Saberi, Omid Delfi, Peter J. Browett, Purvi M. Kakadia, Stefan K. Bohlander

Blood (2023) 142 (Supplement 1): 5763.

https://doi.org/10.1182/blood-2023-180293

Published: 2023

Journal Articles

Venetoclax Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild-Type Populations

Blood (2023) 142 (Supplement 1): 423.

https://doi.org/10.1182/blood-2023-185321

Published: 2023

Journal Articles

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy

Blood (2023) 141 (11): 1316–1321.

https://doi.org/10.1182/blood.2022018602

Published: 2023

Includes: Supplemental data

Journal Articles

Clinical Response to Azacytidine (AZA) Is Associated with Increased Contribution from Mutated Blood Progenitors: Insights from Single Cell Genotyping of Matched Stem/Progenitor and Mature Blood Cells from MDS/CMML Patients Pre- and Post-AZA Treatment

Blood (2022) 140 (Supplement 1): 9751–9752.

https://doi.org/10.1182/blood-2022-163158

Published: 2022

Journal Articles

In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial

Blood (2022) 140 (Supplement 1): 6927–6929.

https://doi.org/10.1182/blood-2022-157634

Published: 2022

Journal Articles

Clonal Evolution in a Murine CALM-AF10 Leukemia: Evidence of Functional Heterogeneity of Leukemia Stem Cells

Niloofar Zandvakili, Hui Mei Lee, Rhea Desai, Alyona Oryshchuk, Peter J. Browett, Purvi M Kakadia, Stefan K. Bohlander

Blood (2021) 138 (Supplement 1): 1158.

https://doi.org/10.1182/blood-2021-154068

Published: 2021

Journal Articles

MLL/AF9 Expression Causes Leukemia in Zebrafish

Maryam Saberi, Omid Delfi, Dona Wathsala Madola, Peter J. Browett, Purvi M Kakadia, Stefan K. Bohlander

Blood (2021) 138 (Supplement 1): 4330.

https://doi.org/10.1182/blood-2021-154125

Published: 2021

Journal Articles

Characterization of an Acute Myeloid Leukemia Murine Model Driven By MLL/AF9: Effect of Retroviral Insertion Sites and Somatic Mutations on Gene Expression

Hui Mei Lee, Niloofar Zandvakili, Rhea Desai, Peter J. Browett, Purvi M Kakadia, Stefan K. Bohlander

Blood (2021) 138 (Supplement 1): 4329.

https://doi.org/10.1182/blood-2021-154012

Published: 2021

Journal Articles

A Murine Immunocompetent Acute Myeloid Leukemia (AML) Model for Testing Immunotherapies

Hui Mei Lee, Niloofar Zandvakilli, Rhea Desai, PhD, Purvi M Kakadia, PhD, Peter Browett, BMedSci, MBChB, FRACP, FRCPA, Stefan K. Bohlander, MD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-141171

Published: 2020

Journal Articles

Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study

Chong Chyn Chua, MBBS, John Reynolds, PhD, Jessica M Salmon, PhD, Chun Fong, Stephen B Ting, MB BS, FRACP, FRCPA, PhD, Ing Soo Tiong, MBBS,FRACP,FRCPA, Shaun Fleming, MBBS,, Sarah MacRaild, Donia M Moujalled, PhD, Giovanna Pomilio, Nik Cummings, Julie McManus, Adam Ivey, BSc, MSc, PhD, Purvi M Kakadia, PhD, Stefan K. Bohlander, MD, Andrew W. Roberts, MBBS, PhD FRACP, FRCPA, Andrew H. Wei, PhD FRACP, FRCPA, MBBS

Blood (2019) 134 (Supplement_1): 462.

https://doi.org/10.1182/blood-2019-126640

Published: 2019

Journal Articles

Characterization of Cooperating Mutations in Murine Acute Leukemias: Towards Establishing Leukemia Models with Genetic Lesions in Defined Cellular Pathways

Sarvenaz Taghavi, Rhea Desai, Jenny Chien, PhD, Heidi Super, PhD, Peter Browett, MBChB, Purvi M Kakadia, PhD, Stefan K. Bohlander, MD

Blood (2017) 130 (Supplement 1): 3944.

https://doi.org/10.1182/blood.V130.Suppl_1.3944.3944

Published: 2017

Journal Articles

Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis

Blood (2014) 124 (8): 1304–1311.

https://doi.org/10.1182/blood-2013-12-540716

Published: 2014

Includes: Supplemental data

Journal Articles

A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)

Blood (2013) 122 (21): 1303.

https://doi.org/10.1182/blood.V122.21.1303.1303

Published: 2013

Journal Articles

Acute Myeloid Leukemia With Isolated Trisomy 13 Is a Genetically Homogenous Entity With a High Frequency Of Mutations In Genes Encoding Components Of The Splicing Machinery and Extremely Poor Prognosis

Blood (2013) 122 (21): 608.

https://doi.org/10.1182/blood.V122.21.608.608

Published: 2013

Journal Articles

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

Blood (2013) 122 (10): 1761–1769.

https://doi.org/10.1182/blood-2013-01-476473

Published: 2013

Includes: Supplemental data

Journal Articles

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

Blood (2013) 121 (18): 3650–3657.

https://doi.org/10.1182/blood-2012-10-458695

Published: 2013

Includes: Supplemental data

Journal Articles

Analysis of Cooperating Genetic Events in MLLT3-MLL Rearranged Acute Myeloid Leukemia (AML) by Targeted Next-Generation Sequencing of 16 Leukemia-Related Genes Reveals Frequent Mutations Affecting Growth Factor Signalling Pathways and Provides Evidence for Clonal Heterogeneity

Klaus H. Metzeler, MD, Nadine Sandhöfer, Tanja Hinrichsen, Evelyn Zellmeier, Bianka Ksienzyk, Annika Dufour, PhD, Stephanie Schneider, PhD, Purvi M. Kakadia, PhD, Philipp A Greif, MD, Marion S. Subklewe, MD, Stefan K Bohlander, MD, Hanns-Georg Klein, MD, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD

Blood (2012) 120 (21): 1379.

https://doi.org/10.1182/blood.V120.21.1379.1379

Published: 2012

Journal Articles

Exome Sequencing Identifies Recurring FLT3 N676K Mutations in Core Binding Factor Leukemia

Sabrina Opatz, Harald Polzer, Tobias Herold, MD, Nikola P Konstandin, Bianka Ksienzyk, Alexander Graf, Stefan Krebs, PhD, Helmut Blum, PhD, Karl Peter Hopfner, PhD, Purvi M. Kakadia, PhD, Stephanie Schneider, PhD, Annika Dufour, PhD, Jan Braess, MD, Michael Heuser, MD, Wolfgang Hiddemann, MD, PhD, Karsten Spiekermann, MD, Stefan K Bohlander, MD, Philipp A Greif, MD

Blood (2012) 120 (21): 404.

https://doi.org/10.1182/blood.V120.21.404.404

Published: 2012

NARROW

Signaling Pathway Mutations Cooperate with the PICALM/MLLT10 Fusion in a Knock-in AML Mouse Model

Picalm/MLLT10 Expression in Zebrafish Is Associated with an Increase of Hematopoietic Stem Cells and Leads to Leukemia

Drug Repurposing in a Zebrafish AML Model

Venetoclax Has Potent Efficacy in NPM1 mutated AML with Acquired Resistance Associated with Either Perturbed Pro-Survival Signalling or NPM1 wild-Type Populations

Contribution of mutant HSC clones to immature and mature cells in MDS and CMML, and variations with AZA therapy

Clinical Response to Azacytidine (AZA) Is Associated with Increased Contribution from Mutated Blood Progenitors: Insights from Single Cell Genotyping of Matched Stem/Progenitor and Mature Blood Cells from MDS/CMML Patients Pre- and Post-AZA Treatment

In Vivo Drug Incorporation and Intracellular Dynamics of Injectable Versus Oral Azacytidine: A Phase II Open Label Multicentre Trial

Clonal Evolution in a Murine CALM-AF10 Leukemia: Evidence of Functional Heterogeneity of Leukemia Stem Cells

MLL/AF9 Expression Causes Leukemia in Zebrafish

Characterization of an Acute Myeloid Leukemia Murine Model Driven By MLL/AF9: Effect of Retroviral Insertion Sites and Somatic Mutations on Gene Expression

A Murine Immunocompetent Acute Myeloid Leukemia (AML) Model for Testing Immunotherapies

Anti-Leukemic Activity of Single Agent Venetoclax in Newly Diagnosed Acute Myeloid Leukemia: A Sub-Set Analysis of the Caveat Study

Characterization of Cooperating Mutations in Murine Acute Leukemias: Towards Establishing Leukemia Models with Genetic Lesions in Defined Cellular Pathways

Isolated trisomy 13 defines a homogeneous AML subgroup with high frequency of mutations in spliceosome genes and poor prognosis

A Combined Molecular and Clinical Prognostic Index For Relapse and Survival In Cytogenetically Normal AML (PINA)

Acute Myeloid Leukemia With Isolated Trisomy 13 Is a Genetically Homogenous Entity With a High Frequency Of Mutations In Genes Encoding Components Of The Splicing Machinery and Extremely Poor Prognosis

Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia

Inactivation of TP53 correlates with disease progression and low miR-34a expression in previously treated chronic lymphocytic leukemia patients

Analysis of Cooperating Genetic Events in MLLT3-MLL Rearranged Acute Myeloid Leukemia (AML) by Targeted Next-Generation Sequencing of 16 Leukemia-Related Genes Reveals Frequent Mutations Affecting Growth Factor Signalling Pathways and Provides Evidence for Clonal Heterogeneity

Exome Sequencing Identifies Recurring FLT3 N676K Mutations in Core Binding Factor Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only